Contents
Osteoporosis is a condition in which bones become weaker because bone mineral density, bone mass, or bone structure has changed. Weakened bones are more likely to fracture, sometimes after a minor fall, bump, or everyday movement that would not normally cause a break.
Because bone loss usually develops without noticeable symptoms, osteoporosis is often called a silent bone disease. A fracture may be the first clear sign that bone strength has declined.
A dual-energy X-ray absorptiometry scan, commonly called a DXA or DEXA scan, is the primary test used to measure bone mineral density. Laboratory testing serves a different but complementary purpose. Blood and urine tests may help uncover vitamin deficiencies, hormone imbalances, kidney problems, malabsorption, or other health conditions that can contribute to bone loss.
Ulta Lab Tests provides direct access to many laboratory tests related to bone metabolism, nutrition, hormones, and organ function. Explore the osteoporosis laboratory testing category or review the Bone Health Test Panel.
Laboratory testing provides useful health information but does not diagnose osteoporosis, replace a DXA scan, or substitute for professional medical advice. Review your results, symptoms, fracture history, and imaging findings with a qualified healthcare provider.
Bone is living tissue that is continually renewed through a process called bone remodeling. Specialized cells remove older or damaged bone while other cells build new bone.
During childhood and early adulthood, bone formation generally keeps pace with or exceeds bone breakdown. With aging—and under the influence of menopause, certain medical conditions, nutritional deficiencies, reduced activity, or medications—bone breakdown may begin to exceed bone formation.
Osteoporosis develops when the resulting loss of bone mass or deterioration of bone structure makes the skeleton less able to withstand normal stress. The hip, spine, and wrist are among the sites most frequently affected by osteoporosis-related fractures.
Osteoporosis-related fractures can affect mobility, independence, posture, and quality of life. Hip fractures may require surgery and lengthy rehabilitation. Vertebral compression fractures can contribute to chronic pain, loss of height, reduced mobility, and a rounded upper-back posture.
Earlier awareness of bone loss may help patients and healthcare providers evaluate fracture risk, investigate contributing factors, improve fall-prevention strategies, and determine whether additional monitoring or treatment should be considered.
Osteopenia, also called low bone mass, means bone mineral density is below the expected young-adult range but has not reached the DXA threshold generally used to classify osteoporosis.
For postmenopausal women and men age 50 and older, DXA T-scores are generally classified as follows:
| T-Score | General Classification |
|---|---|
| -1.0 or higher | Normal bone mineral density |
| Between -1.0 and -2.5 | Low bone mass or osteopenia |
| -2.5 or lower | Osteoporosis |
A T-score is not the only factor that matters. A hip or vertebral fragility fracture may establish osteoporosis clinically even when the T-score is above -2.5. In younger adults, clinicians often place more emphasis on the Z-score, fracture history, medical conditions, and possible secondary causes of bone loss.
Early osteoporosis usually does not cause pain, fatigue, or an obvious change in how a person feels. Bone loss can continue quietly until weakened bone fractures.
Blood calcium may also remain within the laboratory reference range because the body tightly regulates the amount of calcium circulating in the bloodstream. A normal blood calcium result therefore does not confirm that bones are strong or rule out osteoporosis.
Bone mineral density requires imaging. Laboratory testing helps evaluate the biological systems that influence bone formation, mineralization, and breakdown.
Although osteoporosis itself may not cause early symptoms, the following findings warrant medical attention:
Safety note: Seek prompt medical care after a fall or when experiencing severe back or hip pain, inability to stand or bear weight, visible deformity, new weakness or numbness, or loss of bladder or bowel control.
Some osteoporosis risks cannot be changed, while others may be addressed through medical care, nutrition, physical activity, medication review, and fall prevention.
| Symptom or Risk Factor | What It May Suggest | Related Evaluation or Laboratory Tests |
|---|---|---|
| Low-trauma fracture | Reduced bone strength or an underlying bone disorder | DXA, vertebral imaging, Vitamin D 25-Hydroxy Total Immunoassay Test, Comprehensive Metabolic Panel Test, PTH Intact Test, and Phosphate as Phosphorus Test |
| Height loss, stooped posture, or back pain | Possible vertebral compression fracture | Medical imaging, DXA, and laboratory evaluation for secondary causes |
| Menopause or increasing age | Accelerated or age-related bone loss | Clinical fracture-risk assessment, DXA when appropriate, Vitamin D 25-Hydroxy Total Immunoassay Test, and metabolic testing |
| Long-term glucocorticoid use | Medication-associated bone loss | DXA, Vitamin D 25-Hydroxy Total Immunoassay Test, Comprehensive Metabolic Panel Test, and PTH Intact Test |
| Low body weight or restrictive eating | Reduced bone reserve or inadequate nutrient intake | Complete Blood Count with Differential and Platelets, Comprehensive Metabolic Panel Test, Vitamin D 25-Hydroxy Total Immunoassay Test, Magnesium Test, and Phosphate as Phosphorus Test |
| Celiac disease, inflammatory bowel disease, or bariatric surgery | Possible nutrient malabsorption | ULTA Celiac Disease Screen, Vitamin D 25-Hydroxy Total Immunoassay Test, Comprehensive Metabolic Panel Test, and PTH Intact Test |
| Hyperthyroidism or excessive thyroid hormone exposure | Increased bone turnover | TSH Test or TSH and Free T4 Test |
| Abnormal calcium or chronic kidney disease | Disruption of mineral, vitamin D, phosphorus, and PTH regulation | Comprehensive Metabolic Panel Test, PTH Intact Test, Phosphate as Phosphorus Test, and Magnesium Test |
| Possible low testosterone in men | Hormonal contribution to bone and muscle loss | Testosterone Total Test with healthcare-provider-directed follow-up |
| Frequent falls, weakness, or poor balance | Increased fracture risk even without very low bone density | Medical and fall-risk evaluation; selected testing may include a Complete Blood Count with Differential and Platelets, Comprehensive Metabolic Panel Test, and Vitamin D 25-Hydroxy Total Immunoassay Test |
The U.S. Preventive Services Task Force recommends osteoporosis screening for women age 65 and older. It also recommends screening postmenopausal women younger than 65 who have one or more risk factors and are found to have increased fracture risk through a clinical risk-assessment process.
Evidence for universal screening in men is less definitive. Other professional organizations commonly recommend DXA testing for men age 70 and older and for younger men who have meaningful osteoporosis risk factors.
People who may need earlier evaluation include those with:
A healthcare provider may also use the Fracture Risk Assessment Tool, or FRAX, to estimate a person’s 10-year probability of hip fracture and major osteoporotic fracture. FRAX incorporates clinical risk factors and may include femoral-neck bone mineral density.
No single blood test can diagnose osteoporosis. Diagnosis and fracture-risk assessment rely primarily on medical history, fracture history, physical examination, DXA imaging, and, when appropriate, vertebral imaging.
Laboratory tests help answer a different question:
Is a nutritional deficiency, hormone imbalance, organ disorder, malabsorption problem, or other secondary factor contributing to bone loss?
Laboratory testing may provide information about:
A blood or urine test cannot directly measure the density, architecture, or strength of the hip or spine. It also cannot independently determine whether a person will experience a fracture.
Normal laboratory results do not rule out osteoporosis, and abnormal results do not automatically prove that bone loss is present. Laboratory findings must be interpreted alongside DXA results, age, health history, medications, nutrition, and fracture risk.
| Laboratory Test | What It Measures | Why It May Be Relevant | Important Limitations |
|---|---|---|---|
| Bone Health Test Panel | Combines multiple laboratory markers related to nutrients, minerals, hormones, and bone metabolism. | May offer a convenient starting point for reviewing several factors that influence bone health. | The panel does not replace DXA imaging or a provider-directed evaluation. Review the included tests before ordering to avoid unnecessary duplication. |
| Vitamin D 25-Hydroxy Total Immunoassay Test | Measures the primary circulating form used to assess vitamin D status. | Vitamin D supports calcium absorption, muscle function, and bone mineralization. A low result may occur with limited intake, reduced sun exposure, malabsorption, obesity, or certain health conditions and medications. | Routine testing is not necessary for every person. The active form of vitamin D is generally not the preferred test for routine vitamin D status. |
| Comprehensive Metabolic Panel Test | Includes calcium, albumin, creatinine, estimated kidney function, liver markers, electrolytes, and alkaline phosphatase. | May identify abnormalities involving calcium balance, albumin, kidney function, liver function, or alkaline phosphatase that warrant further investigation. | Serum calcium does not measure bone density. Total calcium may be affected by albumin levels. |
| PTH Intact Test | Measures intact parathyroid hormone, an important regulator of calcium and phosphorus. | An abnormal result may be associated with parathyroid disease, vitamin D deficiency, chronic kidney disease, or altered calcium balance. | PTH should generally be interpreted with calcium, vitamin D, phosphorus, and kidney-function results. |
| PTH Intact Test with Ionized Calcium | Measures parathyroid hormone together with the biologically active portion of circulating calcium. | May provide additional information when total calcium is abnormal or difficult to interpret. | Results still require interpretation with vitamin D, phosphorus, kidney function, medications, and clinical history. |
| Phosphate as Phosphorus Test | Measures phosphorus in the blood. | Phosphorus works with calcium in bone mineralization and is affected by PTH, vitamin D, kidney function, and nutrition. | A single result does not diagnose osteoporosis or identify its cause. |
| Magnesium Test | Measures serum magnesium. | Magnesium contributes to bone structure, muscle function, vitamin D metabolism, and PTH regulation. | Serum magnesium may not reflect total body magnesium stores and should be interpreted in context. |
| TSH Test | Measures thyroid-stimulating hormone. | A suppressed TSH may suggest excessive thyroid hormone exposure or hyperthyroidism, which can accelerate bone turnover. | TSH should be interpreted with symptoms, medications, and additional thyroid testing when appropriate. |
| TSH and Free T4 Test | Evaluates thyroid regulation and circulating free thyroxine. | Provides a broader evaluation when abnormal thyroid function may be contributing to bone loss. | Additional thyroid testing may still be needed depending on the results and clinical history. |
| Complete Blood Count with Differential and Platelets | Measures red blood cells, white blood cells, hemoglobin, hematocrit, and platelets. | Anemia or other blood-cell abnormalities may prompt evaluation for nutritional deficiency, chronic illness, malabsorption, or a hematologic condition. | CBC abnormalities are not specific to osteoporosis and require appropriate medical follow-up. |
| Testosterone Total Test | Measures total testosterone. | Low testosterone may contribute to reduced bone and muscle health in men and may warrant further hormonal evaluation. | A single testosterone result should not be used alone to diagnose hypogonadism. Timing, symptoms, repeat testing, and additional hormones may be important. |
| ULTA Celiac Disease Screen | Measures antibodies associated with celiac disease. | Celiac disease can interfere with the absorption of calcium, vitamin D, iron, and other nutrients that support bone health. | Testing is generally most informative while consuming gluten. Positive screening results require clinical confirmation. |
| Calcium 24 Hour Urine Test with Creatinine | Measures calcium excretion over a full day and uses creatinine to help assess collection completeness. | May support evaluation of calcium absorption, urinary calcium loss, kidney stones, or parathyroid-related concerns. | Incomplete collection can significantly affect results. Diet, medications, supplements, and kidney function also influence interpretation. |
| Serum Protein Electrophoresis Test | Separates and measures major protein fractions in serum. | May be considered when unexplained osteoporosis, anemia, kidney problems, high protein, bone pain, or other findings raise concern for a plasma-cell disorder. | This is not a routine test for everyone with low bone density. Abnormal results require provider-directed follow-up. |
| Collagen Type I C-Telopeptide Test | Measures CTX fragments released during type I collagen breakdown and reflects bone resorption. | May help establish a baseline or monitor changes in bone breakdown during selected osteoporosis treatments. | CTX is not a stand-alone osteoporosis screening or diagnostic test. Fasting, collection time, kidney function, recent fractures, and assay methodology can influence results. |
| Procollagen Type I Intact N-Terminal Propeptide Test | Measures P1NP, a marker released during type I collagen formation. | May help assess bone-formation activity and monitor response to selected osteoporosis therapies. | P1NP does not diagnose osteoporosis by itself. Serial testing is most useful when timing and laboratory methodology are kept consistent. |
| Bone Specific Alkaline Phosphatase Test | Measures an alkaline phosphatase fraction associated primarily with bone-forming cells. | May provide information about bone-formation activity in selected clinical circumstances. | It should not be interpreted as a direct measure of bone density or fracture risk. |
| Collagen Cross-Linked N-Telopeptide Urine Test | Measures urinary NTX, a marker associated with type I collagen breakdown. | May be used to evaluate or monitor bone-resorption activity in selected patients. | Hydration, collection conditions, kidney function, and normal biological variation may affect the result. |
Not everyone needs every test. The appropriate laboratory evaluation depends on age, sex, fracture history, DXA results, symptoms, medications, medical conditions, nutrition, and the suspected cause of bone loss.
A foundational evaluation for someone with osteoporosis, significant osteopenia, or a fragility fracture may include:
The Bone Health Test Panel may provide a convenient way to assess several bone-related markers. Review the panel components before ordering so that tests are not duplicated unnecessarily.
Additional testing may be appropriate when symptoms or medical history suggest a specific contributor:
Bone-turnover markers can change sooner than bone mineral density and may be helpful when monitoring selected osteoporosis therapies. Options include:
These markers should not be used alone to diagnose osteoporosis or predict an individual fracture. Their value is greatest when a healthcare provider defines why the test is being ordered and how the result will influence monitoring.
Laboratories may use different instruments, methodologies, units, and reference populations. Compare each result with the reference interval printed on your own laboratory report rather than relying on a range found online.
A standard reference range describes results from a defined comparison population. An “optimal” range may reflect a particular guideline, clinician, research study, or wellness program and may not be universally accepted. Ask what evidence supports any target being recommended for you.
A person can have normal calcium, vitamin D, kidney, thyroid, and parathyroid results and still have osteoporosis. Laboratory testing and DXA imaging answer different health questions.
Hydration, meals, supplements, medications, specimen timing, recent illness, physical activity, kidney function, and normal biological variation may affect laboratory results. Repeat or confirmatory testing may be appropriate before conclusions are made.
Changes over time can provide important context, especially for vitamin D and bone-turnover markers. When monitoring a result, try to use the same laboratory and similar collection conditions whenever possible.
The Collagen Type I C-Telopeptide Test is often most comparable when collected fasting in the morning. The Testosterone Total Test is also commonly collected in the morning. Always follow the preparation instructions provided for the exact test ordered.
DXA and laboratory findings are most valuable when they support a personalized bone-health plan. Depending on health history and fracture risk, a healthcare provider may discuss:
Do not begin high-dose calcium, vitamin D, hormone therapy, or osteoporosis medication based solely on an online article or one laboratory result. Excessive supplementation can cause harm, and medication decisions require an individualized assessment.
Consider discussing laboratory testing with a healthcare provider when you:
Preparation requirements vary according to the tests selected.
Ulta Lab Tests enables consumers to order many laboratory tests directly online where available. Pricing is displayed before purchase, insurance is not required, and eligible HSA or FSA payment methods may be accepted.
Specimen collection is performed through established laboratory networks where applicable, and results are delivered securely online. Patients can use their results to have more informed conversations with physicians and other qualified healthcare providers.
Ulta Lab Tests does not perform DXA imaging, diagnose osteoporosis, prescribe treatment, or replace professional medical evaluation.
Explore your options:
Common laboratory tests may include the Vitamin D 25-Hydroxy Total Immunoassay Test, Comprehensive Metabolic Panel Test, PTH Intact Test, Phosphate as Phosphorus Test, Magnesium Test, Complete Blood Count with Differential and Platelets, and TSH Test. These tests look for contributors to bone loss but do not replace a DXA scan.
No. Blood calcium measures the calcium circulating in your bloodstream, not the mineral content or strength of your bones. Blood calcium may remain normal even when bone density is low. Calcium-related testing may help evaluate parathyroid, kidney, vitamin D, or metabolic problems that influence bone health.
A DXA scan of the hip and spine is generally the primary test used to measure bone mineral density and classify osteoporosis. Healthcare providers may also consider fracture history, vertebral imaging, T-scores, Z-scores, fall risk, medications, and FRAX estimates. Blood and urine tests help investigate contributing causes rather than making the diagnosis by themselves.
In postmenopausal women and men age 50 or older, a T-score of -2.5 or lower at an accepted skeletal site meets the bone-density classification for osteoporosis. A T-score between -1.0 and -2.5 indicates low bone mass or osteopenia. Fracture history and overall fracture risk must also be considered.
Vitamin D helps the body absorb calcium, while parathyroid hormone regulates calcium and phosphorus. Low vitamin D may stimulate PTH production, and abnormal PTH can alter bone remodeling. Reviewing the Vitamin D 25-Hydroxy Total Immunoassay Test, PTH Intact Test, calcium, phosphorus, and kidney function together provides more context than any one result alone.
The Collagen Type I C-Telopeptide Test measures CTX, a marker of bone resorption or breakdown. The Procollagen Type I Intact N-Terminal Propeptide Test measures P1NP, a marker of bone formation. They may help monitor selected osteoporosis treatments but should not be used alone to screen for or diagnose osteoporosis.
Excess thyroid hormone can accelerate bone turnover and contribute to bone loss. A suppressed result on a TSH Test may occur with hyperthyroidism or excessive thyroid-hormone exposure. A TSH and Free T4 Test may provide additional information. Thyroid medication should not be changed without guidance from the prescribing healthcare provider.
Yes. Celiac disease can damage the small intestine and interfere with the absorption of calcium, vitamin D, iron, and other nutrients needed for bone health. The ULTA Celiac Disease Screen may be appropriate when osteoporosis occurs with anemia, digestive symptoms, low body weight, nutrient deficiencies, or other signs of malabsorption.
Testosterone contributes to bone density, muscle mass, and physical function. Persistently low testosterone may be one contributor to male osteoporosis. A properly timed Testosterone Total Test can provide useful information, but diagnosis generally requires compatible symptoms, repeat measurement, and additional clinical evaluation.
Ulta Lab Tests provides direct online access to many vitamin D, metabolic, hormone, celiac, mineral, and bone-turnover tests where available. These tests do not replace DXA imaging or a medical evaluation. Results should be reviewed with a qualified healthcare provider who can relate them to symptoms, fractures, medications, and bone-density findings.
There is no single testing schedule for everyone. Repeat DXA timing depends on age, initial bone density, fracture risk, treatment status, and the expected rate of change. Laboratory testing may be repeated to confirm an abnormal result, monitor vitamin D or mineral balance, or evaluate a treatment response. A provider should define what is being monitored and how the result will influence care.
Osteoporosis deserves attention precisely because it can remain silent until a fracture occurs. Understanding personal risk, obtaining DXA screening when appropriate, and investigating possible contributors to bone loss can support earlier and more productive conversations with a healthcare provider.
A DXA scan remains central to measuring bone mineral density. Laboratory tests add another layer of information by evaluating vitamin D status, calcium and phosphorus regulation, kidney function, thyroid function, parathyroid hormone, sex hormones, nutrient malabsorption, and bone turnover.
Explore the osteoporosis laboratory testing options available through Ulta Lab Tests. Review your results alongside your DXA findings, medical history, medications, and fracture risk with a qualified healthcare professional.
Osteoporosis definition: Osteoporosis is a bone disease in which decreased bone density, bone mass, or structural strength increases the risk of fractures. It is called a silent disease because bone loss usually causes no symptoms until a fracture or vertebral compression occurs.
Related laboratory tests: Vitamin D 25-Hydroxy Total Immunoassay Test, Comprehensive Metabolic Panel Test, PTH Intact Test, Phosphate as Phosphorus Test, Magnesium Test, TSH Test, Testosterone Total Test, ULTA Celiac Disease Screen, Calcium 24 Hour Urine Test with Creatinine, Collagen Type I C-Telopeptide Test, and Procollagen Type I Intact N-Terminal Propeptide Test.
How Ulta Lab Tests helps: Ulta Lab Tests provides direct online access to many laboratory tests related to bone health, with transparent pricing and secure online results.
Laboratory testing is informational and should be interpreted with DXA findings, medical history, and guidance from a qualified healthcare provider.
The Bone Health Test Panel is Ulta Lab Tests’ consolidated panel for evaluating multiple factors related to bone metabolism and health.
These tests evaluate vitamin D status, calcium and albumin within the CMP, phosphorus, magnesium, kidney function, liver markers, and other metabolic factors relevant to bone health.
These tests help evaluate parathyroid hormone activity, biologically active calcium, and urinary calcium excretion.
These tests assess thyroid function and testosterone status, which may be relevant when hormonal factors are suspected in bone loss.
These tests may help identify anemia, possible nutrient malabsorption associated with celiac disease, or abnormal serum protein patterns when clinically relevant.
P1NP and bone-specific alkaline phosphatase are laboratory markers associated with bone-formation activity.
CTX and NTX measure breakdown products associated with type I collagen and are used as bone-resorption or bone-turnover markers in selected monitoring situations.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
